For Research Use Only. Melanotan II is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans.
The metabolic effects of Melanotan II reflect the combined contributions of multiple melanocortin receptors engaged simultaneously. MC4R in central feeding circuits reduces food intake as documented in the MC4R appetite article. MC5R in adipose tissue promotes lipolysis as documented in the MC5R lipolysis article. Additional central MC4R effects on sympathetic outflow contribute to energy expenditure modulation.
The integrated metabolic profile therefore includes reduced energy intake, increased lipolytic substrate mobilization, and modest effects on energy expenditure. The combination produces an energy deficit that drives the body composition changes documented in published research. The multi-receptor engagement distinguishes Melanotan II from selective MC4R agonists that would produce only the central effects without the peripheral MC5R lipolytic component.
The Nature subject hub on melanocortin system and the Cell Press journal Cell Metabolism archive primary research on the integrated melanocortin metabolic biology.
Body Composition Changes
Published Melanotan II research in rodent obesity models documents body weight reduction during treatment periods, with the weight loss coming preferentially from fat mass rather than lean mass. Body composition analysis using DEXA or dissection methods confirms the preferential fat loss pattern.
The body composition changes reflect the integrated metabolic profile. Reduced food intake produces the energy deficit. Increased lipolysis in response to MC5R activation makes adipose stores the preferential substrate for the energy deficit. The sympathetic and adrenergic effects from central MC4R activation further support fat mobilization. The combined effects produce the body composition shift toward reduced fat mass.
The body composition research can be compared with the body composition effects of other metabolic peptides in the Midwest Peptide catalog. The GLP-1 SM body composition article covers incretin receptor agonist effects. The GLP-3 RT body composition article covers triple agonist effects. The cagrilintide weight maintenance article covers amylin analog effects. Each compound produces body composition changes through different mechanisms, and the melanocortin approach of Melanotan II represents yet another mechanistic entry point into body composition modulation.
Energy Balance Components
The energy balance equation has three main components: energy intake, energy expenditure, and substrate utilization. Melanotan II affects all three. The appetite suppression reduces energy intake. The sympathetic activation modestly increases energy expenditure. The lipolytic effect shifts substrate utilization toward fat oxidation. The integrated effect on energy balance produces the body composition changes documented in research models.
Published research using indirect calorimetry has examined the energy expenditure component specifically, with findings of modest increases in resting energy expenditure during Melanotan II treatment. The magnitude is smaller than what is documented for the glucagon receptor component of GLP-3 RT triple agonist research covered in the energy expenditure article, but contributes to the overall energy deficit.
Substrate utilization measured by respiratory exchange ratio shows shifts toward fat oxidation during treatment, consistent with the MC5R lipolytic effects providing fatty acid substrate for oxidation. The shifted substrate utilization profile is another component of the integrated metabolic effect.
Glucose Regulation Effects
Central MC4R signaling has documented effects on glucose regulation through autonomic pathways that affect pancreatic hormone secretion and peripheral glucose disposal. Published Melanotan II research documents modest improvements in glucose regulation endpoints in obese rodent models, with the improvements likely reflecting both the body composition improvement and the direct effects of central MC4R activation on glucose homeostasis.
The glucose regulation effects connect to the incretin and amylin research in adjacent clusters through the shared metabolic framework. The GLP-1 SM glucose article covers glucose regulation from the incretin perspective. The cagrilintide glucagon crosstalk article covers glucose regulation from the amylin perspective. Different compounds address glucose regulation through different primary mechanisms, and comparative research characterizes the distinctions.
The ScienceDirect glucose regulation topic page archives primary research on the integrated biology.
Lipid Profile Effects
Circulating lipids including triglycerides, cholesterol, and free fatty acids have been measured in Melanotan II research. The findings document reduced circulating triglycerides during treatment, consistent with the body composition improvements and the reduced hepatic triglyceride synthesis that accompanies reduced visceral adiposity. Free fatty acid levels show transient elevations during acute lipolysis periods with normalization over longer treatment periods as the body composition adjusts.
The lipid profile effects integrate with the broader metabolic profile. Improved body composition reduces the metabolic inputs that drive unfavorable lipid profiles. Direct MC5R effects on adipocyte metabolism affect the balance between lipid storage and mobilization. The combined lipid profile changes support the overall cardiovascular risk factor reduction that emerges from the metabolic improvements.
The Wiley Online Library lipid metabolism collection archives primary research on metabolic lipid biology.
Inflammatory Markers
Circulating inflammatory markers decline during Melanotan II treatment in obese rodent models, reflecting both the reduced visceral adipose inflammation and the direct anti-inflammatory effects of MC1R activation documented in the MT-1 anti-inflammatory article that also apply to Melanotan II through shared MC1R engagement.
The combined metabolic and anti-inflammatory effects produce a comprehensive improvement in the metabolic inflammation profile. This is one of the features that distinguishes Melanotan II from more selective MC4R agonists that would not have the MC1R mediated anti-inflammatory component.
The inflammatory profile research connects to the GLP-2 TZ inflammation article which covers inflammation in the dual incretin context, and to the KLOW anti-inflammatory article which covers direct anti-inflammatory approaches.